Examkin

Soru

Zorluk: ZorNeoplastic Processes

A 64-year-old man comes to the oncology clinic for a follow-up evaluation. Three months ago, he was diagnosed with metastatic cutaneous melanoma. Molecular profiling of the tumor tissue revealed a valine-to-glutamic acid substitution at codon 600 of the BRAF gene (BRAF V600E). He was subsequently started on targeted oral monotherapy with vemurafenib. Today, the patient reports the rapid appearance of several raised, crusted skin lesions on his extensor forearms and trunk over the last 3 weeks. Physical examination shows multiple 1 cm1 \text{ cm} to 2 cm2 \text{ cm} hyperkeratotic, dome-shaped nodules with central keratinous plugs. A shave biopsy of one of the lesions confirms well-differentiated squamous cell carcinoma. Which of the following cellular mechanisms best explains the development of this patient's new cutaneous neoplasms?

  1. A
    Direct alkylation of DNA leading to unrepairable strand breaks and escape from cell cycle arrest
  2. Paradoxical dimerization and hyperactivation of RAF kinases in cells with wild-type BRAFCevap
  3. C
    Pharmacologic suppression of cellular immunosurveillance permitting proliferation of latent oncogenic viruses
  4. D
    Inhibition of nucleotide excision repair enzymes leading to rapid accumulation of ultraviolet-induced mutations
  5. E
    Constitutive activation of epidermal growth factor receptors due to loss of negative feedback loops

Cevap

Paradoxical dimerization and hyperactivation of RAF kinases in cells with wild-type BRAF
The correct answer accurately identifies that BRAF inhibitors (such as vemurafenib) block the mutant BRAF V600E kinase but, in normal cells with wild-type BRAF, they induce RAF dimerization. If these wild-type cells harbor an upstream RAS mutation (such as an HRAS mutation common in sun-damaged skin), the dimerization leads to paradoxical hyperactivation of the downstream MEK/ERK (MAPK) pathway. This intense proliferative signal drives the rapid formation of keratoacanthomas and cutaneous squamous cell carcinomas. To prevent this, BRAF inhibitors are now standardly co-administered with MEK inhibitors (e.g., trametinib), which block the pathway downstream of RAF.

Adım Adım Çözüm

1
Identify the patient's primary disease and current treatment.
The patient has metastatic melanoma with a BRAF V600E mutation and is being treated with vemurafenib, a selective BRAF inhibitor.
Establishing the specific pharmacologic intervention is required to determine its unique adverse effect profile.
2
Characterize the new clinical finding based on history, physical examination, and biopsy results.
The patient has developed new eruptive skin nodules that are histologically confirmed to be well-differentiated squamous cell carcinomas (or keratoacanthomas).
Recognizing this specific secondary malignancy is key to diagnosing the drug-induced complication.
3
Link the adverse effect to the molecular mechanism of the targeted therapy.
Vemurafenib causes paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in cells that do not possess the BRAF V600E mutation.
Understanding the cellular and molecular consequences of targeted kinase inhibition is essential for managing oncologic toxicities.

Anahtar Kavram

BRAF inhibitors (e.g., vemurafenib, dabrafenib) can induce secondary cutaneous squamous cell carcinomas and keratoacanthomas through paradoxical activation of the RAF/MEK/ERK (MAPK) signaling pathway in wild-type BRAF cells, often driven by upstream HRAS mutations.
Bu soruyu puanla

Konular

Neoplastic Processes

Bu konudan daha fazla soru